[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354002-105":59,"doc-detail-354002-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","impact-of-prior-cancer-history-on-survival-in-patients-with-adenocarcinoma-of-esophagogastric-junction-retrospective-cohort-study-using-seer-database","Impact of Prior Cancer History on Survival in Patients with Adenocarcinoma of Esophagogastric Junction - Retrospective Cohort Study Using SEER Database","","Prior cancer history is often excluded from oncology clinical trials, yet its prognostic value in adenocarcinoma of the esophagogastric junction (AEG) remains insufficiently defined. This retrospective cohort study used SEER data (1975–2021) to quantify prior-cancer prevalence and evaluate overall and cancer-specific survival. Among 10,895 AEG patients, 16.58% had prior cancer, which independently worsened overall survival but not cancer-specific survival, with several subgroups showing neutral outcomes.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/impact-of-prior-cancer-history-on-survival-in-patients-with-adenocarcinoma-of-esophagogastric-junction-retrospective-cohort-study-using-seer-database/354002/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/impact-of-prior-cancer-history-on-survival-in-patients-with-adenocarcinoma-of-esophagogastric-junction-retrospective-cohort-study-using-seer-database/354002.png","ImageObject",300,407,{"name":92,"@type":93},"Alex Sinclair","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study goal regarding prior cancer history in AEG patients?","Question",{"text":112,"@type":113},"To assess how prior cancer affects survival in patients with adenocarcinoma of the esophagogastric junction, and to generate evidence for refining clinical trial eligibility criteria.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What data source and patient selection criteria were used?",{"text":117,"@type":113},"The study used the SEER database for 1975–2021 and included 10,895 AEG patients with histologically confirmed disease, complete follow-up, and only one prior cancer before the index AEG diagnosis.",{"name":119,"@type":110,"acceptedAnswer":120},"How did prior cancer history influence survival outcomes?",{"text":121,"@type":113},"Prior cancer history was independently associated with worse overall survival (adjusted HR 1.16) but showed no significant association with cancer-specific survival (HR 1.03). Some subgroups, such as patients with prior cancer diagnosed within 1 year, demonstrated comparable or improved cancer-specific survival.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354002,1790795043,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},1099523882182,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Original Article  \nImpact of prior cancer history on survival in patients with adenocarcinoma of esophagogastric junction: a retrospective cohort study using SEER database  \nHongkun Lai1, Jianlong Zhou1, Jiabin Zheng1, Huolun Feng1, Lixue Cao2, Baohua Hou3, Yong Li1  \n1Department of Gastrointestinal Surgery, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China; 2Medical Research Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China; 3Department of General Surgery, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China  \nContributions: (I) Conception and design: All authors; (II) Administrative support: L Cao, B Hou, Y Li; (III) Provision of study materials or patients: L Cao, B Hou, Y Li; (IV) Collection and assembly of data: H Lai, J Zhou, J Zheng, H Feng; (V) Data analysis and interpretation: H Lai, J Zhou; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.  \nCorrespondence to: Yong Li, MD, PhD. Department of Gastrointestinal Surgery, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, No. 106, Zhongshan 2nd Road, Yuexiu District, Guangzhou 510080, China. Email: [liyong@gdph.org](liyong@gdph.org). cn; Baohua Hou, MD, PhD. Department of General Surgery, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, No. 106, Zhongshan 2nd Road, Yuexiu District, Guangzhou 510080, [China. Email: hbh1000@126.com](China. Email: hbh1000@126.com); Lixue Cao, PhD. Medical Research Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, No. 106, Zhongshan 2nd Road, Yuexiu District, Guangzhou 510080, China. Email: [caolixue@gdph.org.cn](caolixue@gdph.org.cn).  \nBackground: The exclusion of patients with prior malignancies from clinical trials remains controversial, yet its prognostic impact on adenocarcinoma of esophagogastric junction (AEG) is poorly characterized.  \nThis retrospective cohort study aimed to evaluate the prevalence and survival implications of prior cancer in  \nAEG patients, providing evidence for refining trial eligibility criteria.  \nMethods: The Surveillance, Epidemiology, and End Results databases were used to collect data between 1975 and 2021, and 10,895 AEG patients were included in the study. Inclusion required histologically confirmed AEG with complete follow-up data and only those with one prior cancer preceding the index AEG diagnosis to ensure temporal clarity. Prior cancers were classified according to their primary site, frequency, stage, and timing. Survival analyses included Kaplan-Meier curves, multivariate Cox regression, and competing risk models (Fine and Gray’s). Propensity score matching was applied as a sensitivity analysis  \nto validate the robustness of the primary findings.  \nResults: Among 10,895 eligible patients, 16.58%(n=1,806) had prior cancer history and a median age of 67 years, with 79.20% male patients. The cohort showed significantly different overall survival (median 13 months for prior cancer vs. 16 months for no prior cancer) . Disease stage distribution was: localized (18.40%), regional (28.80%), distant (29.30%), and unstaged (23.50%) . The most common types of prior cancer were prostate (28.07%), and colon and cecum (11.13%) . Additionally, 38.7% of the prior tumors were staged localized disease at prior cancer diagnosis. The median time period between detection of first and subsequent malignancies was 6.0 years. Patients with prior cancer were older (median age: 73 vs.  \n67 years) and had higher rates of localized AEG (23.30% vs. 17.50%, P\u003C0.001) but lower chemotherapy utilization (46.50% vs. 57.50%, P\u003C0.001) or radiation therapy (37.60% vs. 42.50%, P\u003C0.001) . Prior cancer was independentl","cbCaioqKZqUv653N","https://ap.wps.com/l/cbCaioqKZqUv653N","pdf",1579574,28,"English","# Background\n# Methods\n# Results\n## Cohort characteristics and survival impact\n## Subgroup and competing risk analyses\n# Conclusions\n# Keywords","[{\"question\":\"What was the study goal regarding prior cancer history in AEG patients?\",\"answer\":\"To assess how prior cancer affects survival in patients with adenocarcinoma of the esophagogastric junction, and to generate evidence for refining clinical trial eligibility criteria.\"},{\"question\":\"What data source and patient selection criteria were used?\",\"answer\":\"The study used the SEER database for 1975–2021 and included 10,895 AEG patients with histologically confirmed disease, complete follow-up, and only one prior cancer before the index AEG diagnosis.\"},{\"question\":\"How did prior cancer history influence survival outcomes?\",\"answer\":\"Prior cancer history was independently associated with worse overall survival (adjusted HR 1.16) but showed no significant association with cancer-specific survival (HR 1.03). Some subgroups, such as patients with prior cancer diagnosed within 1 year, demonstrated comparable or improved cancer-specific survival.\"}]","Impact of Prior Cancer History on Survival in Patients with Adenocarcinoma of Esophagogastric Junction - Retrospective Cohort Study Using SEER Database | PDF",1790108430,71]